OBJECTIVES: The World Health Organization guidelines recommend that an increase of potassium intake reduce blood pressure in adults. In addition, intervention with vitamin B2 has been shown to lower blood pressure in patients with genotype, specifically in hypertensive patients with premature cardiovascular disease (CVD) homozygous for the 677C→T polymorphism (TT genotype) in the gene encoding for the enzyme methylenetetrahydrofolate reductase. In the Chinese northern region, the prevalence of this TT genotype was estimated to be 35% of the population. Furthermore, 26% of adults are hypertensive and 20% adults will experience a CVD episode.This study aims to evaluate the impact of increased intake of potassium and vitamin B2 have on blood pressure, CVD events and quality-of-life among Chinese adults older than 45 years old. Furthermore this study assesses the costs and cost-effectiveness of achieving this impact via the consumption of a fortified milk product. METHODS: An analytical decision model was used to quantify and compare three strategies against the current intake of the at-risk-population: 1) Increased potassium intake level 2) Increased vitamin B2 intake level 3) Combined increased vitamin B2 and potassium intake levels. The effectiveness of these strategies in incrementing vitamin B2 and potassium were determined by patient level data and the Framingham methodology. All costs and epidemiological data were collected from the literature. RESULTS: All strategies led to statistically significant health outcomes due to the preventive effect of increased intake of potassium and vitamin B2 also resulting in a significant Quality Adjusted Life Years gain over the baseline.  Each strategy is shown to be cost-effective or highly cost-effective with the largest effect being the combined increased intake of potassium and vitamin B2. CONCLUSIONS: The strategy of the combined increased intake of vitamin B2 and potassium is highly cost-effective thereby preventing CVD events and saving costs to the health system.